SPONSOR

Institute of Hematology & Blood Diseases Hospital, China

Total Trials

Recruiting

Phases

Phase 2, EARLY_Phase 1, Phase 1

Conditions studied: AML (Acute Myelogenous Leukemia)Multiple Myeloma Relapse Acute Myeloid Leukemia Acute Lymphoblastic Leukemia, Adult Precursor Cell Lymphoblastic Leukemia-Lymphoma Acute Myeloid Leukemia Hemophilia Hemophilia A Hemophilia B Myelodysplastic Syndrome

Institute of Hematology & Blood Diseases Hospital, China is a clinical research sponsor with 27 registered studies on ClinicalTrials.gov, of which 27 are actively recruiting participants. Research covers conditions including AML (Acute Myelogenous Leukemia), Multiple Myeloma, Relapse Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult.

The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Institute of Hematology & Blood Diseases Hospital, China

How many clinical trials has Institute of Hematology & Blood Diseases Hospital, China sponsored?

ClinicalMetric currently tracks 27 clinical trials sponsored by Institute of Hematology & Blood Diseases Hospital, China, of which 27 are actively recruiting participants. These trials cover conditions including AML (Acute Myelogenous Leukemia), Multiple Myeloma, Relapse Acute Myeloid Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Institute of Hematology & Blood Diseases Hospital, China research focus on?

Institute of Hematology & Blood Diseases Hospital, China clinical trials span AML (Acute Myelogenous Leukemia), Multiple Myeloma, Relapse Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Institute of Hematology & Blood Diseases Hospital, China clinical trial?

To participate in a Institute of Hematology & Blood Diseases Hospital, China trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Institute of Hematology & Blood Diseases Hospital, China trials with current recruitment status updated daily.

Institute of Hematology & Blood Diseases Hospital, China

Frequently Asked Questions — Institute of Hematology & Blood Diseases Hospital, China

Clinical Trials by Institute of Hematology & Blood Diseases Hospital, China

Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

National Longitudinal Cohort of Hematological Diseases

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL

A Study of FVIII Gene Therapy for Hemophilia A

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Immune Reconstitution Characteristics and Influencing Factors Following Umbilical Cord Blood Transplantation

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML